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Concepts for aminoglycoside serum level
monitoring
Aminoglycosides are broad spectrum anti-
biotics of great value in the management of
severe Gram-negative infections. These drugs
are characterized by a low therapeutic index
which can be partly explained by their
pharmacokinetic behaviour: namely an up-
take into renal tissue with a slow terminal
elimination (Kahlmeter, Jonsson & Kamme,
1978;SchentageM/., 1978; Wenke/a/., 1979,
1980). The clinical use of aminoglycosides is
difficult because of the great variability of
serum levels on standardized dosage; a further
problem is the dependency of the elimination
rate on renal function. Therefore, monitoring
of aminoglycoside serum levels is rec-
ommended to ensure adequate bactericidal
concentrations and to reduce the risks of
nephro- and ototoxicity. Despite considerable
efforts, however, safe dosage regimens to
prevent toxic effects are still lacking.
The attempts to provide the means for
improved therapeutic monitoring were more
successful, as today at least one dozen
different methods are available to measure
aminoglycosides in biological fluids. These
methods include microbiological plate
diffusion assay (bioassay), radioenzymic assay
(REA) radio-immunoassay (RIA), enzyme-
immunoassay (EIA) and high-performance
liquid chromatography (HPLC) (for meth-
odological reviews see Maitra el al, 1979;
Reeves, 1980).
How should the routine laboratory select
the most suitable method? This question
cannot be generally answered as every
laboratory is faced with different working
conditions. However, careful consideration of
the established criteria, such as specificity,
sensitivity, accuracy, time requirement, ex-
penses for trained personnel and reagents, is
very useful. In addition, the aminoglycoside
measurements should be coordinated with
the overall drug monitoring programme of a
hospital, which not only includes the amino-
glycoside antibiotics, but also the whole
spectrum of drugs, fulfilling the basic require-
ments for serum level determinations
(Richens&Warrington, 1979).
What does this mean for the choice of an
assay to measure aminoglycoside antibiotics?
First, to reduce costs for equipment and
personnel, there is no longer a justification to
develop a separate assay technique for every
single drug included in a monitoring pro-
gramme. It is more reasonable to use a limited
number of assay systems which can deal with
most of the drugs selected for serum level
determinations. Some of the more popular
aminoglycoside analyses have to be discussed
in the light of this concept. The bioassay is
probably still the most widespread method,
but the reasons for this are historical rather
than objective advantage. The bioassay is
non-specific and time consuming, and its
accuracy can be very poor if the method is not
performed under skillful supervision. The
latter implies additional efforts in personnel
and cost, an aspect which is very often dis-
regarded by authors discussing this method.
The radioenzymic assay is a highly reliable
tool to measure aminoglycosides, but it also
needs close attention and an expensive liquid
scintillation counter. Furthermore, this
method cannot be used for any other drug.
High-performance liquid chromatography
as well as immunological methods belong to
the techniques applicable to a wide variety of
organic substances: they are sensitive, ac-
curate and highly specific. Unfortunately, the
aminoglycosides can be assayed by HPLC
only after pre- or postcolumn derivatisation,
because they have a poor UV-absorption in
their un-derivated state (Anhalt & Brown,
1978). In addition, HPLC is relatively
inflexible for routine use, especially if
different drugs have to be analysed regularly.
This drawback might be overcome either by
the rather expensive way of using a separate
HPLC equipment for each drug or by adding a
column switching device to have different
equilibrated columns at hand. This technique
can also be used for an on-line sample clean-
up, a very promising new way for the sample
preparation (Ernie/ al., 1981).
Radioimmunoassays are commercially
available for most aminoglycosides and also
for a great number of other drugs. If a
Leading articles 169
laboratory is working predominantly with
RIAs it has to deal with assays from several
different manufacturers. This can be a serious
source of errors. Furthermore, the limited
shelf-life and the hazards of working with
radioactive materials are other disadvantages
of the radioimmunoassay. However, because
of its extreme sensitivity, RIA will still be the
method of choice for certain pharmacokinetic
studies.
At present, there is a trend leading away
from radioimmunoassay to non-radioactive
enzyme-immunoassays or fluoroimmuno-
assays. In fact, the commercially available
homogenous enzyme-immunoassay (EMIT,
Syva Corp., Palo Alto, CA) would well fit into
the more generalized monitoring concept
mentioned above. With this technique it is not
only possible to measure the aminoglycosides
(gentamicin and tobramycin are already
available, reagents for netilmicin and
amikacin are in preparation), but also several
other drugs requiring therapeutic monitoring,
e.g. antiepileptics, antiarrhytymics, theophyl-
line and methotrexate. The relative high costs
for the EMIT kits are partially compensated
by the great saving in time, and furthermore,
economies are possible by automated pro-
cedures. Another promising non-radioactive
immunological technique is the fluoro-
immunoassay, but so far the reagents for only
a limited number of drugs are available.
Whichever assay is used, one should always
keep in mind that only accurate blood level
determinations are of value for the clinician
and, above all, for the patient. The intro-
duction of commercially available tests,
which are easy to perform, and consequently
also permit smaller laboratories to carry out
drug level determinations, may lead to a
rather uncritical handling of the results. An
extensive quality control program, which
should include external control samples, is
therefore another essential aspect of drug
analysis. The importance of quality controls
was demonstrated by Reeves (1974). In a
survey of the accuracy of gentamicin analysis
among more than 80 laboratories only about
20% of the participants produced satisfactory
results. At that time, however, mostly bio-
assays were used. The current results of the
quality control program organized by the
American Association of Clinical Chemistry
looks much more optimistic, especially for
those laboratories performing their deter-
minations by RIA or EMIT.
The potential benefit of rational thera-
peutic drug monitoring is now widely
accepted. Education in clinical pharmacology
as a new clinical speciality is also established
in most medical universities (Spector, Roberts
& Vessell, 1981). This is an important
requirement, as drug level measurements
without expert advice by a clinical pharma-
cologist or by a clinician trained in this field
are often of questionable value. The avail-
ability of sophisticated analytical techniques
should not distract our attention from the
clinical situation and the aim of amino-
glycoside monitoring. There is always a
danger of treating the serum levels rather than
the patients.
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